leisure time -WSS

leisure time

author：focus 2025-09-29 19:05:57 - browse：2492

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Burning questions for the 2024 JPM Healthcare Conference

focus

entertainment

WSS

Federal weight loss drug coverage is 30 years out of date

The biotech scorecard for Q1: 17 stock

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Testing for cancer recurrence creates a new limbo for patients

Diversifying clinical trials isn't enough to close racial gaps: study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Testing for cancer recurrence creates a new limbo for patients

Bright Health sells Medicare Advantage business to Molina

Emergency medicine has repudiated 'excited delirium.' Now what?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Medicare proposal to cover medical devices draws a mixed reaction

New weight loss drugs work. But how can they best be used?

Jerome Adams on the need for new antivirals for Covid

Hospitals warn Medicare's drug payment fix is ‘unlawful’

focus

Eli Lilly to pay $200M for Beam’s stake in gene

Meta's Zuckerberg and Chan on track to put $50 billion into science

Diversifying clinical trials isn't enough to close racial gaps: study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Diversifying clinical trials isn't enough to close racial gaps: study

Wikipedia

focus

entertainment

hotspot